Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, for use in the treatment of diseases or disorders that can be alleviated by sGC activation or potentiation, selected from chronic liver diseases, Non-Alcoholic Steatohepatitis (NASH), cirrhosis and portal hypertension.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: The disclosure relates to compositions and methods of treating cancer in a subject. The method comprises administering to a patient in need of treatment an effective amount of imipramine.

Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.

Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.

Abstract: A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof, or a hydrate or solvate thereof as an active ingredient.

Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.

Abstract: The present application relates to stable pharmaceutical compositions for oral administration comprising a progesterone alone, or optionally in combination with an estradiol. The pharmaceutical compositions may further include a solubilizing agent, a surfactant and optionally other pharmaceutical acceptable excipients. Preferably, the estradiol does not precipitate for at least 12 months, and the pharmaceutical compositions are stable for at least 12 months under normal storage conditions at room temperature. Also, when the pharmaceutical compositions are stored for 6 months at 40° C./75% relative humidity (RH), the level of Impurity-M in the composition is less than about 0.2% (w/w) as measured by HPLC. The pharmaceutical compositions may be used for the treatment of moderate to severe vasomotor symptoms due to menopause in post-menopausal women.

Abstract: A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of 8,9-unsaturated sterols in the OPCs, the agent comprising a compound having the formula (I): wherein variables Y1, R1 and R2 are as defined herein.

Abstract: A method of ameliorating cachexia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a steroidal lactone is provided. In particular, the steroidal lactone may be withanolide A (WFA) or derivatives thereof. In particular, the method of treatment inhibits development of cachexia associated with ovarian cancer, as well as the induction of cardiac atrophy. Administration of WFA modulates expression of genes that activate satellite cells and inhibit myofibrillar atrophy.

Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.

Abstract: Disclosed herein are methods for inhibiting ectopic calcification in soft tissues, such as heart tissue. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors.

Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Abstract: Provided herein are oligosaccharide compositions for administration to animals suitable for improving animal health, including, for example, to treat diseases or disorders or to enhance animal growth.

Abstract: The invention belongs to the field of biomedicine, and particularly relates to a glucose core, comprising a glucose and/or a glucose hydrate, a diluent and a binder, wherein, the glucose and/or the glucose hydrate is present in the glucose core in an amount of ?85% by weight percentage; and relates to a glucose pellet comprising the glucose core and a laminated layer coating the glucose core; and further relates to a pharmaceutical composition comprising the glucose pellet. The glucose pellet or the pharmaceutical composition of the invention are useful in treatment and/or assistant treatment of a glycogen storage disease and/or a diabetes.

Abstract: A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione, in particular neurodegenerative disease, depression, anxiety, decreased/low motivation, impaired cognitive function, mild cognitive impairment. The composition contains an effective amount of a combination of a Nicotinamide Adenine Dinucleotide (NAD+) precursor and at least one ketone or ketone precursor. The composition can be an enterally administered composition such as an orally administered food product or food supplement.

Abstract: Provided in accordance with the present disclosure are methods for preventing or reducing cognitive dysfunction or decline associated with an acquired brain injury, for treating cognitive dysfunction or decline associated with an acquired brain injury, and for inducing or increasing neuroplasticity, the methods comprising administering to a subject in need thereof a therapeutically effective amount of trehalose.

Abstract: The purpose of the present invention is to provide an agent for preventing or ameliorating Alzheimer's disease, said agent being able to effectively suppress the accumulation of amyloid ? proteins using a safe material, which has been used in foods for many years, and improve spontaneous alternation behavior change ratio. Ceramides (in particular, a glucosylceramide originating in Amorphophallus konjac) can effectively suppress the accumulation of amyloid ? proteins and thus enables the prevention or amelioration of Alzheimers disease.

Abstract: A method of treating a tumor in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of: i) Pembrolizumab; and ii) a lipid having a structural formula as illustrated in FIG. 1 (AGI-134).

Abstract: The present invention is directed to methods for treating, delaying, slowing the progression of and/or preventing disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) canagliflozin and (b) one or more ACE inhibitors or one or more ARBs or one or more PPAR-gamma agonists; and to methods for treating, delaying, slowing the progression of and/or preventing fatty liver disorders (for example, NASH or NAFLD), comprising administering to a subject in need thereof a therapeutically effective amount of canagliflozin.

Abstract: Provided herein are method for treating liver diseases. The methods include administering to the subject a therapeutically effective amount of at least one FXR agonist and a therapeutically effective amount of SAMe. In various embodiments, the at least one FXR agonist and SAMe are administered sequentially or simultaneously.

Abstract: The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-? (TGF-?) signal and/or extracellular matrix (ECM).

Abstract: The invention is directed to methods of treating TNBC in a patient by administering to the patient an agent that inhibits the expression or activity of cyclin-dependent kinase 19 (CDK19). In some embodiments, the agent may be a small molecule inhibitor, a polynucleotide (e.g., shRNA. siRNA), or a protein (e.g., an antibody). In some embodiments, the agent does not inhibit the activity or expression of CDK8.

Abstract: Disclosed are compositions and methods that use lysine demethylase inhibitors for inhibiting the growth of cancer stem cells or tumor initiating cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells and/or for preventing cancer recurrence.

Abstract: The invention discloses a composition comprising glycyrrhizin, hyaluronic acid or a salt or a derivative thereof, and a viscosizing agent. The composition therefore finds advantageous application in all those cosmetic and therapeutic indications in which glycyrrhizin is used, since the composition according to the invention significantly improves the bioavailability thereof.

Abstract: Techniques regarding treating one or more microbe infections with combination therapy are provided. For example, one or more embodiments described herein can comprise a method, which can comprise enhancing an antimicrobial activity of an antibiotic by a combination therapy. The combination therapy can comprise the antibiotic and a polycarbonate polymer functionalized with a guanidinium functional group.

Abstract: The object of the present invention is to provide a therapeutic agent for hyperphosphatemia capable sufficiently decreasing a serum phosphorus concentration with a small dose, and particles therefor. The present invention provides a therapeutic agent for hyperphosphatemia, which comprises, as an active ingredient, a particle containing a crosslinked polymer having a substituent containing a NRA1RA2 structure or a salt thereof, wherein the particle has an average particle diameter of 20 to 150 ?m and a swelling rate of 9 to 16 mL/g (wherein RA1 and RA2 each independently represent a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, an aminoalkyl group having 1 to 20 carbon atoms or a salt thereof, or the like).

Abstract: Provided herein are populations of ex vivo expanded umbilical cord blood-derived regulatory T cells. Also provided are methods of making and using the same.

Abstract: Provided is a composition for treating nerve injury, the composition including a natural killer cell, an immune cell, or a substance increasing activity thereof. According to the natural killer cell, the immune cell, or the substance increasing activity thereof according to an aspect, the natural killer cell may infiltrate into a nerve injury site to directly remove injured nerve cells, thereby being usefully applied to fundamental treatment of a nervous system disease caused by nerve injury or abnormal nerves.

Abstract: A use of a pharmaceutical composition in preparing a drug against Helicobacter pylori. The pharmaceutical composition is suitable for oral administration and comprises a homogeneous mixture of edible oil, beeswax, and ?-sitosterol. The beeswax in the composition forms microcrystals. Based on the total weight of the composition, the content of the beeswax is 0.5-50%, and the content of the ?-sitosterol is 0.1-20%. The pharmaceutical composition can be used in inhibiting or killing Helicobacter pylori and in treating or preventing a disease caused by Helicobacter pylori.

Abstract: The present disclosure provides methods and treatment regimens for treating an inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC), in a subject in need thereof. The present disclosure further provides adjusting a dosing regimen for fecal-microbiome therapy of IBD based on a level of a fecal marker for intestinal inflammation. Further provided are methods comprising providing a therapeutic dosing regimen to a patient with a gastrointestinal disorder (e.g., IBD) in need thereof, the method comprising administering to the patient a therapeutic composition comprising fecal microbes based upon a level of a fecal marker for intestinal inflammation. An exemplary fecal marker is calprotectin. This disclosure also provides a method for screening or selecting a fecal donor by testing efficacy of the donor's fecal material in inducing desirable changes in a fecal marker for intestinal inflammation in an IBD patient (e.g., UC patient).

Abstract: The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.

Abstract: Provided herein are bacterial compositions that are useful for treating and preventing complications and side effects associated with an inflammatory bowel disease.

Abstract: Provided herein are recombinant microorganisms that express a subject polypeptide. Microorganisms can comprise an expression construct comprising a flagellin promoter operatively linked with a heterologous nucleotide sequence encoding the subject polypeptide. The flagellin promoter sequence can comprise a genetic modification that reduces CsrA inhibition of translation. Microorganisms also can comprise a genetic modification that reduces FlgM inhibition of SigD initiation of transcription. The target polypeptide can be an aldehyde dehydrogenase. Such microorganisms are useful in the treatment of alcohol hangover.

Abstract: The present invention relates to compositions comprising galactooligosaccharides (GOS) and probiotic bacteria obtained by a process comprising the step of growing the bacteria in a medium comprising GOS, such composition having the effect of boosting the synbiotic effect of the probiotic bacteria with the GOS. Health benefits of the probiotic bacteria as obtained by such a fermentation process are also contemplated.

Abstract: A vaginitis pathogen-inhibiting composition comprises a fermentate of lactic acid bacteria, which is generated by jointly fermenting a lactic acid bacteria strain and Streptococcus thermophilus in a medium containing at least one of milk, powdered milk, and casein. The lactic acid bacteria strain includes an AP-32 strain of Lactobacillus salivarius subsp. Salicinius; an F-1 strain of Lactobacillus rhamnosus; a GL-165 strain of Lactobacillus rhamnosus; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a Bv-889 strain of Bifidobacterium breve; or combinations thereof. The above-mentioned fermentate of the lactic acid bacteria strain can inhibit growth of vaginitis pathogens and may be in form of a food composition, a pharmaceutical composition, or a vagina-cleaning composition.

Abstract: Lactobacillus-based probiotic compositions for inclusion in microbial-based products. In one instance, the microbial-based product takes the form of an animal feed additive. When used as a feed additive for animals, especially ruminants, and in particular cattle, the following benefits from the composition are noted: (i) improved milk yield in dairy cattle, (ii) improved milk composition in dairy cattle, (iii) increased weight gain-to-feed intake ratio in beef cattle (feed efficiency), and (vi) improved average daily weight gain. Another marked benefit of the compositions when used as an animal feed additive is inhibition of pathogenic growth including E. coli, Salmonella, Clostridium, Staphylococcus and Streptococcus.

Abstract: The present invention relates to a bacteriophage composition comprising at least one bacteriophage species, at least one ?-linked polymeric glucose and at least one polyol. In certain embodiments, the ?-linked polymeric glucose has a mean molecular weight of greater than 10 kDa.

Abstract: A pharmaceutical composition includes a preparation of virus-like particles (VLPs) obtained from the gastrointestinal tract of a subject and a pharmaceutically-acceptable carrier. The VLPs can include bacteriophages, eukaryotic viruses, or gene transfer agents. A VLP composition may be administered to a subject having, or at risk of having dysbiosis, in an amount effective to amelio-rate at least one symptom or clinical sign of dysbiosis. A VLP composition also may be administered to a subject in preparation for administering a source of bacteria, to improve the receptivity of subject's gut to source of bacteria.

Abstract: The present disclosure provides a liquid formulation suitable for a group B adenovirus, comprising: a) a group B adenovirus, such as replication competent group B adenovirus, b) 15 to 25% v/v glycerol, for example 16, 17, 18, 19, 20, 21% v/v glycerol; and c) 0.1 to 1.5% v/v ethanol, for example 0.2-1%, such as 1% v/v ethanol; and d) a buffer, and e) optionally an amino acid, wherein the pH of the formulation is in the range 8.0 to 9.6, and use of the same in treatment, particular in the treatment of cancer.

Abstract: Provided herein are antigenically stealthed HSV particles, and methods of use of the antigenically-stealthed HSV particles.

Abstract: The present disclosure provides methods for treating and preventing foot pain, muscle soreness, inflammation or an inflammatory-related disorder, and itch with the administration of compositions comprising pine resin. Also provided are methods of repelling an insect by applying to a subject composition comprising pine resin.

Abstract: Described herein is a synergistic composition of substances of natural origin, particularly effective in the treatment and prevention of osteoarticular diseases, such as rheumatoid arthritis and osteoarthritis. The composition includes the synergistic combination of aescin, at least one extract of a plant belonging to the genus Boswellia, and an extract of Scutellaria baicalensis. The synergistic composition may be provided in the form of pharmaceutical composition, food supplement, medical device, food for special medical purposes, or a cosmetic.

Abstract: The present invention is directed to an all natural treatment for asthma. The treatment is in liquid form and uses no toxic chemicals or preservatives. The composition includes ginger juice, apple cider vinegar, lemon, honey, CBD oil, and garlic.

Abstract: The present invention relates to a stable parenteral dosage form with a ready-to-inject sterile stable aqueous solution of Cetrorelix acetate. The invention also relates to an injection device prefilled with the ready-to-inject sterile stable aqueous solution of Cetrorelix acetate. The present invention relates a method of inhibiting premature luteinizing hormone surges in women undergoing controlled ovarian stimulation comprising a stable parenteral dosage form with a ready-to-inject sterile stable aqueous solution of Cetrorelix acetate.

Abstract: A method of treating cancer in a mammalian patient comprising administering a pharmaceutical composition to the patient including a pharmacologically effective amount of a first therapeutic, wherein the first therapeutic comprises one or more HER2-targeted peptide functional groups grafted onto a cyclic scaffold, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. In a further embodiment, the one or more HER2-targeted peptide functional groups grafted onto a cyclic scaffold contains at least one 3-amino 3(1-napthyl) propionic acid bound to the scaffold.

Abstract: A use of a tail fiber protein in the prevention of Acinetobacter baumannii infections is disclosed. The tail fiber protein from bacteriophages is coated or sprayed on carriers (such as pipelines and medical devices in hospitals) to inhibit biofilm formation of Acinetobacter baumannii and further prevent Acinetobacter baumannii infections.

Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.

Abstract: The invention provides H-NOX proteins for the delivery of oxygen to hypoxic tissue following stroke. H-NOX proteins extravasate into hypoxic penumbra associated with stroke and preferentially accumulate for sustained delivery of oxygen to the hypoxic tissue to ameliorate adverse affects of stroke related hypoxia. In some embodiments, the H-NOX comprises PEGylated H-NOX and non-PEGylated H-NOX.